Generic Medicine Info
Indications and Dosage
Adult: 250 mg bid or tid. Max: 1,200 mg daily.
Renal Impairment
CrCl (mL/min) Dosage
<30 Contraindicated.
30-60 250 mg 1-2 times daily.
Should be taken with food. Take w/ or after meals.
Peptic ulcer. Severe renal impairment (CrCl <30 mL/min).
Special Precautions
Renal impairment (CrCl 30-60 mL/min).
Adverse Reactions
Peripheral vasodilatation, resulting in flushing, itching and sensation of heat; rash, erythema, heartburn, epigastric pain, nausea, diarrhoea, headache, myalgia, arthralgia, dry eye, malaise, myositis. Rarely, urticaria, angioedema, bronchospasm.
Monitoring Parameters
Monitor hepatic and renal function. Measure lipid profile before treatment and serum lipids periodically.
Drug Interactions
Risk of myopathy is increased when nicotinic acid is given concomitantly w/ a statin, as acipimox is structurally related to nicotinic acid, caution should be taken when used w/ such agents.
Description: Acipimox inhibits the release of fatty acids from adipose tissue and reduces the blood concentrations of VLDL and LDL w/ a subsequent overall reduction in triglyceride and cholesterol levels.
Absorption: Rapidly and completely absorbed from the GI tract. Time to peak plasma concentration: W/in 2 hr.
Excretion: Via urine. Plasma half-life: Approx 2 hr.
MIMS Class
Dyslipidaemic Agents
ATC Classification
C10AD06 - acipimox ; Belongs to the class of nicotinic acid and derivatives. Used in the treatment of hyperlipidemia.
Anon. Acipimox. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 10/06/2016.

Buckingham R (ed). Acipimox. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 10/06/2016.

Joint Formulary Committee. Acipimox. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 10/06/2016.

Pfizer New Zealand Ltd. Olbetam 250 mg Capsules data sheet 08 January 2014. Medsafe. Accessed 10/06/2016.

Disclaimer: This information is independently developed by MIMS based on Acipimox from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
  • Olbetam
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in